Founded in 1995, SOSV is a global venture capital firm headquartered in New Jersey. It focuses on seed-to-growth stage investments in deep tech innovations, primarily in bio-tech/life sciences and hardware/robotics sectors, with a commitment to human and planetary health.

National Institutes of Health is a biomedical research agency of the U.S. Department of Health and Human Services, based in Bethesda, Maryland. It is the primary U.S. government organization devoted to biomedical and health research, conducting science through the Intramural Research Program and funding external research through the Extramural Research Program. The NIH comprises 27 institutes and centers and supports about 1,200 principal investigators and more than 4,000 postdoctoral fellows across basic, translational, and clinical research. It has contributed to major advances such as vaccines and therapies and is dedicated to advancing knowledge and translating discoveries into improvements in public health. Established in 1887, NIH operates as a central hub for medical research in the United States.

The National Science Foundation is an independent federal agency in the United States that funds and supports research and education in science and engineering. It funds fundamental research and education across all fields of science and engineering and administers non-dilutive funding programs to aid early‑stage technology development, helping translate discoveries into commercially viable products and services. Through grants and fellowships, the NSF supports researchers, educators, and startups, contributing to innovation and U.S. competitiveness. The agency operates with a substantial budget to advance science, engineering, and STEM education nationwide.

Founded in Boston in 2004, RA Capital is an investment firm specializing in life sciences and drug development. Its team, with backgrounds in biology, chemistry, medicine, and industry experience, invests in early-stage companies with promising technologies and products across healthcare and life science sectors.

Eli Lilly and Company is a global pharmaceutical leader engaged in the discovery, development, manufacture, and sale of medicines. It operates facilities in the United States, Puerto Rico, and many other countries, with products sold in about 135 countries. The company focuses on therapies in neuroscience, cardiometabolic, cancer, and immunology, and also conducts research in animal health and animal agriculture. Lilly supports patient outcomes and education through a philanthropic foundation that funds programs in underserved communities, including STEM education in Indianapolis.

Founded in 1989, OrbiMed is a New York-based healthcare-dedicated investment firm managing approximately $5 billion in assets. It invests across the spectrum of healthcare companies, from private start-ups to large multinational corporations, focusing on biopharmaceuticals, life sciences, digital health, medical devices, and diagnostics sectors globally.

Founded in 2007, Innovate UK is a non-profit organization based in Swindon, UK. It supports businesses across various economic sectors by offering funding services to promote science and technology innovations.

IndieBio is an accelerator that supports startups using biology to solve major problems, delivering four-month programs for companies and teams with ideas. Based in San Francisco with an office in New York, it focuses on life sciences, biotechnology and synthetic biology, investing in seed and early-stage ventures that place biology at the core of their technology across products, processes and software. The program favors teams with two or more co-founders and generally provides equity-based funding in the early stages, often combining direct investments with additional financing options. Founded in 2014, IndieBio operates within the SOSV accelerator network, a global platform that supports portfolio companies through mentorship, resources and cross-border programs.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore, and a global arm through Qiming Venture Partners USA. It manages multiple funds and invests in early and growth-stage companies across technology, information technology, healthcare, new consumer sectors, AI, robotics, semiconductors, software and digital health. The firm emphasizes a hands-on approach, often taking board seats and providing operational guidance to help CEOs scale and reach exits. Through its investments, it has backed hundreds of companies and supported numerous IPOs and M&A outcomes, with unicorns among its portfolio, illustrating breadth and depth across China and international markets.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. Based in Pasadena, California, it provides long-term strategic capital to innovative life sciences and technology companies developing breakthrough therapies, diagnostics, and platforms across biopharma, digital health, agrifoodtech, agtech, and related healthcare fields. Established in 1996, the firm invests across seed, early, and growth stages and leverages its deep industry knowledge, extensive investor networks, and scientific advisory resources to support portfolio companies. The unit also pursues opportunities at the intersection of real estate, life sciences, and technology, reflecting its parent company's sector focus and integrated ecosystem approach. It aims to help entities advance human health by partnering with founders to scale transformative technologies.

Established in 2000 by Bill and Melinda Gates, this foundation is dedicated to enhancing healthcare, reducing extreme poverty globally, and expanding educational opportunities. It operates regionally with offices in Seattle, Washington D.C., New Delhi, Beijing, and London.

Novo Holdings is a Danish holding and investment firm managing the assets of the Novo Nordisk Foundation. Established in 1999, it invests globally in life science companies at all stages of development, with a portfolio also including equities, bonds, real estate, and infrastructure.

Founded in 1986, ARCH Venture Partners is a venture capital firm specializing in investments that bring innovations in life sciences to market. It focuses on companies co-founded by scientists and entrepreneurs, with a strong track record in commercializing technologies from academic research institutions and national laboratories.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.

Founded in Paris in 1972, Sofinnova Partners is a venture capital firm dedicated to life sciences investments. With over €2 billion under management, the firm actively partners with entrepreneurs from seed to later-stage, focusing on biopharmaceuticals, medical devices, and industrial biotechnology. Sofinnova proactively sources deals, often leading Round A financings, and plays an active role in portfolio companies until exit.

Mission BioCapital is a life science venture capital firm investing in early-stage companies within the biotechnology sector. Founded in Cambridge, Massachusetts in 2009, the company is known for its experienced leadership team and deep support provided to portfolio companies.

Founded in 1999, Perceptive Advisors is a New York-based investment firm focused on the life sciences sector. It invests across various stages of company development, from seed to late-stage ventures and public equities, with a typical investment size ranging from $10 million to $200 million. The firm employs long/short equity strategies and conducts in-house research to identify promising opportunities in biotechnology, pharmaceuticals, life sciences, and healthcare services.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, that focuses on biotechnology and life sciences companies in the United States. The firm seeks to invest in pharmaceutical and biotechnology ventures, including oncology and other healthcare technologies, with a goal of supporting entrepreneurs in turning ideas into developed therapies. It emphasizes collaboration with ambitious partners and aims to advance biotech innovation and important new therapies by providing capital and advisory support. The organization also operates as a registered investment adviser, offering investment advisory services to guide portfolio companies through growth and development.

Sanofi is a global pharmaceutical company headquartered in Paris that researches, develops, manufactures, and markets medicines and vaccines for a broad range of diseases. Its portfolio covers diabetes, oncology, immunology, cardiovascular diseases, and rare disorders, along with consumer healthcare products. Sanofi pursues innovation across biologics and small-molecule therapies and maintains a robust vaccine program to address infectious diseases. The company emphasizes patient-oriented research and collaborates with partners to bring new treatments to patients worldwide.

The EIC Accelerator is a Horizon Europe funding program that provides assistance to start-ups and SMEs that have an innovative, game-changing product, service, or business model that has the potential to create new markets or disrupt existing ones, and have the ambition and commitment to scale up, are seeking substantial funding, but the risks involved are too high for private investors to invest alone

Founded in 1999, Versant Ventures is a global healthcare investment firm dedicated to supporting exceptional entrepreneurs building innovative companies. With over $2 billion under management and offices across North America and Europe, the firm invests across all stages of healthcare company development, with a focus on novel therapeutics. Versant's team, with deep investment, operating, and scientific expertise, takes a hands-on approach to company building.

EASME is a European Union executive agency that supports small and medium-sized enterprises and promotes innovation in Europe. It manages projects in the areas of small and medium-sized enterprises, as well as the environment, energy, and maritime sectors, funded by COSME, LIFE, and EMFF. EASME organizes the European Sustainable Energy Week and serves industries such as environmental management, energy production, and maritime activities.

Casdin Capital is a New York‑based investment firm founded in 2012 by Eli Casdin. The firm specializes in fundamental research and long‑short equity strategies focused on the life sciences and healthcare sectors, including oncology, digital health, and agtech. In addition to its public‑market fund, Casdin Capital invests in early‑stage to late‑stage private companies within these industries. It operates as a Registered Investment Adviser and, as of October 2020, managed approximately $2.2 billion in assets.

Invus Financial Advisors, LLC is an employee-owned investment firm based in New York, founded in 2006. The firm specializes in private equity investments and manages pooled investment vehicles, including hedge funds and funds of funds. Invus focuses on making direct and indirect investments in special situations, venture capital, and growth equity stages, with an emphasis on smaller companies and opportunistic co-investments. The firm adopts a flexible approach, recognizing the uniqueness of each company and the complexities of business transformation. Invus maintains a long-term commitment to its investments, aligning its incentives with those of its partners. With a history of empowering owner-managers since 1985 and a strong backing from a group of European families, Invus Financial Advisors manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong.

Redmile Group, established in 2007, is a private equity firm headquartered in San Francisco with an additional office in New York. The company specializes in healthcare investments, focusing on venture capital opportunities within the sector.

Foresite Capital is a healthcare and life sciences investment firm based in Larkspur, California, with offices in San Francisco and New York. The firm pursues growth and expansion investments across the United States in healthcare technology and services, therapeutics, and life sciences. It uses a data-driven, cross-disciplinary approach that combines biology, data science, and clinical insight to identify promising startups and help them scale. Foresite Capital collaborates with portfolio companies through a multidisciplinary team of scientists, engineers, analysts, and clinicians who understand healthcare business models alongside capital. It emphasizes backing companies that apply data science and machine intelligence to address unmet clinical needs and to advance patient care over the long term. Notable areas include genomics, biotherapeutics, diagnostics, and life science tools.

MassChallenge is a global startup accelerator supporting early-stage entrepreneurs across various industries. Founded in 2009, it provides mentorship, resources, and networking opportunities through its programs worldwide.

Founded in 1849, Pfizer is a global pharmaceutical company dedicated to discovering and developing safe, effective, and affordable medicines. With a broad portfolio across various therapeutic areas, Pfizer focuses on wellness, prevention, treatment, and cures for diseases, including investments in emerging technologies to shape the future of healthcare.

Google is a multinational technology company renowned for its search engine, offering services such as Gmail, Google Drive, Google Docs, and YouTube. It specializes in advertising solutions through Google Ads and mobile operating systems with Android, while actively innovating in artificial intelligence and machine learning.

Venture Kick is a Swiss initiative supporting early-stage startups with pre-seed funding and entrepreneurial training. It has awarded over CHF 24.9 million to 600 projects, creating 6,033 jobs and attracting subsequent investments worth CHF 2.49 billion.

Novartis is a global healthcare company based in Switzerland, providing innovative medicines and solutions to address evolving patient needs worldwide. With over 100,000 employees across 140 countries, they focus on discovering new treatments in areas such as oncology, immunology, neuroscience, and cardiovascular diseases.

Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. It provides capital and strategic guidance to startups across stages, focusing on technology-driven companies in areas such as artificial intelligence, climate and sustainability, enterprise software and services, fintech, digital health, medical technology and diagnostics, therapeutics, consumer products, and frontier technologies. The firm backs bold ventures with the potential to disrupt markets and improve lives, supporting companies from early to growth stages and working closely with entrepreneurs to apply science, technology and innovative business models. While primarily investing in North American technology companies, Khosla Ventures pursues opportunities globally and emphasizes experimentation and impact alongside financial returns. The firm also maintains related impact initiatives that support entrepreneurs addressing socio-economic challenges in emerging markets.

Polaris Partners is a venture capital firm based in Boston, Massachusetts, with offices in San Francisco. Founded in 1996, it targets investments in technology and life science companies across the United States and Europe, supporting startups from early formation to profitable growth. The firm's healthcare and biotechnology focus encompasses digital health, consumer-centric care delivery, patient-provider solutions, data science and analytics, as well as therapeutics, genomics and other life science platforms. It backs companies across business-to-business and business-to-consumer models, software as a service, healthcare information technology and health tech sectors, partnering with repeat entrepreneurs to build durable, scale-ready businesses.

Founded in 1986, Morningside Group is a venture capital firm based in the greater Boston area. It invests in companies with innovative science and technology across life sciences, digital health, AI, materials, and technology sectors.

Northpond Ventures is a science-driven venture capital firm based in Bethesda, Maryland, with additional offices in San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the firm concentrates its investments in life sciences, diagnostics, therapeutics, digital health, and related technologies, including AI and machine learning applications in biotech and medical fields, as well as environmental and other emerging technologies. It seeks to back early- and growth-stage companies that advance biomedical research, diagnostics, medical devices, and technology-enabled health solutions. The firm operates as a registered investment adviser and emphasizes building a better tomorrow through science-driven investing. It focuses on strategy, value creation, and supporting companies at the intersection of life sciences and technology, aiming to accelerate innovations that improve health outcomes.

Biotechnology Value Fund is a private investment partnership based in San Francisco, focusing on fundamentally-driven public biotechnology investments. Established in 1993, the fund aims to create concentrated, long-term investments in small-cap biotechnology firms. It emphasizes rigorous due diligence and continuous monitoring of its portfolio to ensure sustainable growth. Furthermore, Biotechnology Value Fund is dedicated to collaborating with its portfolio companies, fostering partnerships that support mutual success in the biotechnology sector.

New Enterprise Associates is a venture capital firm founded in 1977 and based in Menlo Park, California, with offices in the United States, India and China. It makes investments across technology and healthcare startups at multiple stages, from seed to growth, including software, cloud, data, internet services, fintech, AI, e-commerce, and enterprise technology, as well as healthcare information technology, life sciences, medical devices, and biopharma. It also considers energy technology and infrastructure opportunities, such as solar, batteries and smart grids. The firm pursues a global approach, with activity in the United States, Asia and other regions, and supports companies through rounds of financing ranging from small to sizable investments as they scale. NEA focuses on building portfolios in software, IT services, consumer technology, and healthcare technology, backing ambitious entrepreneurs across sectors and geographies.

Surveyor Capital is a fundamental equities business that operates sector-aligned investment teams focusing on market neutral strategies. The company aims to generate alpha by gaining a deep understanding of each company's strategy, management teams, performance drivers, and industry trends over the medium and long term. With a focus on fundamental analysis, Surveyor Capital strives to achieve success through a comprehensive approach to investment in the equities market.

Bristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines across hematology, oncology, cardiovascular, and immunology. Its portfolio includes Opdivo for cancer immunotherapy; Eliquis for stroke prevention and venous thromboembolism; Orencia for rheumatoid arthritis; Sprycel, Yervoy, Empliciti, Baraclude; Reyataz and Sustiva for HIV; and Daklinza, Sunvepra, Beclabuvir for viral infections. The company sells products through wholesalers, retail pharmacies, hospitals, government entities, and medical professionals worldwide, and pursues collaboration and licensing arrangements with Pfizer, Otsuka, Ono, Nektar, AstraZeneca, Insitro, Schrödinger, and others. It also engages in partnerships for discovery and development with multiple biotech firms and academia. Founded in 1887 and headquartered in New York, the firm has a strong presence in immuno-oncology and focuses on innovative therapies and global reach.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, with emphasis on drug discovery and development. It backs early-stage and seed companies in the United States, aiming to build science-driven businesses capable of delivering multiple product opportunities rather than short-term exits. The firm concentrates on oncology and other disease areas including inflammation, infectious disease, metabolic and cardiovascular disorders, and nervous system conditions, seeking to support platform-based discoveries with potential for significant therapeutic impact.

The California Institute for Regenerative Medicine (CIRM) was established in 2005 following the passage of Proposition 71, which aimed to fund stem cell research at California universities and research institutions. With a mandate to support and advance stem cell research and regenerative medicine, CIRM focuses on developing cures, therapies, diagnostics, and research technologies that address chronic diseases and injuries. The organization operates under stringent ethical and medical standards, ensuring that its initiatives contribute positively to human health. CIRM plays a pivotal role in facilitating research through grants and loans, thereby fostering innovation and collaboration within the scientific community. Its efforts are directed towards alleviating human suffering and improving health outcomes through advancements in regenerative medicine.

Cormorant Asset Management, established in 2013 and headquartered in Boston, Massachusetts, is an employee-owned hedge fund sponsor. It offers services to pooled investment vehicles, specializing in investments across both public and private markets within the biotechnology and life sciences sectors.

Deep Track Capital is a venture capital firm focused on life sciences and biotechnology. Based in Greenwich, Connecticut, it partners with management teams of innovative public and pre-IPO companies, offering capital and strategic support through its network and expertise. The firm aims to lead transactions, form large syndicates, and participate in rounds led by other investors, applying time and resources to help portfolio companies grow.

Deerfield Management is a New York-based investment firm established in 1994 that focuses on healthcare. It operates across investment, information, and philanthropy to support the healthcare ecosystem. The firm provides private and public investments and offers long-term, structured capital to both public and private healthcare companies. Its portfolio spans life sciences, medical devices, diagnostics, digital health, and health services. As an investment adviser, it seeks opportunities in healthcare products and services and aims to accelerate innovation by combining capital with industry insight.

The Scottish Investment Bank is a public body supporting economic growth in Scotland. It facilitates finance for small to medium-sized businesses, focusing on sectors such as renewable energy, technology, life sciences, and creative industries. The bank works closely with portfolio companies to strengthen management teams and accelerate growth.

Founded in 1934, Janus Henderson Investors is a global asset management firm headquartered in London. It specializes in delivering investment performance and services to institutional, retail, and high-net-worth clients across various asset classes such as equities, fixed income, property, and alternatives.

SR One is the corporate venture capital arm of GlaxoSmithKline, investing globally in early-stage life science companies pursuing innovative science with the potential to significantly improve medical care. Since 1985, SR One has invested about $800 million in more than 180 companies.

Founded in 1969, F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts. It invests globally in technology and healthcare sectors, supporting entrepreneurs with its extensive domain expertise and relationships.

Forbion is a venture capital firm based in Naarden, Netherlands, established in 2006. It specializes in early-stage investments within the life sciences and MedTech sectors, focusing on companies involved in drug development and addressing critical medical needs. The firm has a team of nine investment professionals and has built a strong track record since the late 1990s, with successful investments in various notable companies. Forbion manages assets exceeding €400 million across three active funds and co-manages BioGeneration Ventures, which targets academic spin-outs and seed investments in the Netherlands. The firm continues to play a significant role in advancing innovative healthcare solutions through its strategic investments.